Cancer Care: The Next Generation

Dr. Gail Roboz on ABC talks about “taking a chance on something new.” [go]

 

 

 

 

 


NewYork-Presbyterian Hospital Ranked as New York Best Hospital

Earlier this week the U.S. News and World Report released their annual survey of “Best Hospitals”. NewYork-Presbyterian one of the country’s largest and most comprehensive hospitals was ranked New York’s No. 1 hospital for the 16th year in a row, and No. 6 ranked hospital in all of the United States. Dr. Augustine M.K. Choi, interim dean of Weill Cornell Medicine commented,

“Our esteemed physicians and scientists at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medicine always put patients first, providing them with the finest, most comprehensive care so that they can live their healthiest lives. Together we create one of the top academic medical centers in the United States, motivated by a shared commitment: to drive excellence in healthcare and truly make a difference in New York and beyond.”

This commitment is shared by the physicians, researchers, and staff in the Leukemia Program.


Dr. Pinkal Desai Discusses a Clinical Trial of SGI-110 for People with MDS/MPN and CMMoL

This clinical study is aimed at men and women with a diagnosis of: Chronic Neutrophilic Leukemia (CNL), Chronic Myelomonocytic Leuekmia (CMML), atypical Chronic Myeloid Leukemia (aCML), Juvenile Myelomonocytic Leukemia (JMML), and Myelodysplastic & Myeloproliferative Neoplasm Unclassifiable (MDS/MPN-U). Click here to learn more or see if you are eligible to participate.


Phase 3 Trial Shows CPX-351 (Vyxeos) Boosts Overall Survival in AML

Frontline treatment with CPX-351 (Vyxeos) significantly boosted overall survival (OS) for older patients with high-risk, secondary acute myeloid leukemia (AML) when compared with the current standard of care, cytarabine and daunorubicin, according to data from a phase III trial released by the drug’s developer, Celator Pharmaceuticals, Inc.
“These findings confirm that Vyxeos provides the first opportunity we’ve had in decades to extend survival for patients with high-risk AML,” added Gail Roboz, MD, Professor of Medicine and Director of the Leukemia Program at the Weill Medical College of Cornell University and the New York-Presbyterian Hospital in New York, said in a statement. “Also, more patients in remission means more who are eligible for potentially curative therapy.” To see the full article and data visit Targeted Oncology

Dr. Gail Roboz Quoted in People Magazine

Dr. Gail Roboz was interviewed by People Magazine about bone marrow donation and transplant.  To read the article click here.


Weill Cornell Cancer Center Highlighted in New York Times

cancer-1-articleLarge   An April 21, 2013 article in the New York Times describes the budding field of Precision Medicine.  The article highlights Weill Cornell’s state-of-the-art Cancer Center and how Precision Medicine is being used to treat patients with Leukemia.  To read the full article, click here.


Dr. Gail Roboz featured in Parade Magazine

Parade  Dr. Gail Roboz was interviewed and photographed alongside Good Morning America anchor and her bone marrow transplant doctor on March 31, 2013.  To read the full article, click here.